CLINICAL TRIALS PROFILE FOR RADICAVA
✉ Email this page to a colleague
All Clinical Trials for RADICAVA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03272503 ↗ | A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) | Recruiting | ALS Canada | Phase 2 | 2017-10-27 | This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis. 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo. Participants will be on study medication up to 22 weeks, and on study up to 26 weeks. There are 8 clinic visits and 1 phone visit over the course of the Treatment Phase of the study. The second phase which is Observational, is optional with follow-up for up to 5 years from the end of the Treatment Phase. |
| NCT03272503 ↗ | A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) | Recruiting | Brain Canada | Phase 2 | 2017-10-27 | This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis. 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo. Participants will be on study medication up to 22 weeks, and on study up to 26 weeks. There are 8 clinic visits and 1 phone visit over the course of the Treatment Phase of the study. The second phase which is Observational, is optional with follow-up for up to 5 years from the end of the Treatment Phase. |
| NCT03272503 ↗ | A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) | Recruiting | University of Calgary | Phase 2 | 2017-10-27 | This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis. 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo. Participants will be on study medication up to 22 weeks, and on study up to 26 weeks. There are 8 clinic visits and 1 phone visit over the course of the Treatment Phase of the study. The second phase which is Observational, is optional with follow-up for up to 5 years from the end of the Treatment Phase. |
| NCT03272802 ↗ | Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) | Unknown status | Isfahan University of Medical Sciences | Phase 2/Phase 3 | 2017-03-16 | Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of 30,000 affected individual every year. Complex nature and unknown pathogenesis of this disease are 2 major reasons for failure of therapeutic interventions. Edaravone is a free radical scavenger that slows down functional decline and prevents from disease progression in ALS patients. FDA newly approved this drug in these patients (2017/5/5). In this study, investigators aimed to assess the treatment effect of this newly approved drug in patients with ALS in a representative Iranian population. |
| NCT03664544 ↗ | PK Study in Subjects With Severe Hepatic Impairment | Completed | Mitsubishi Tanabe Pharma Corporation | Phase 1 | 2018-11-06 | This is an open-label, single-dose study in male and female subjects with severe hepatic impairment and in male and female subjects with normal hepatic function. |
| NCT06107205 ↗ | Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects | Completed | Auzone Biological Technology Pty Ltd | Phase 1 | 2023-11-07 | This is a Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions.The objective is To characterize the bioequivalence、safety and tolerability of TTYP01 tablets and Radicava® injection or Radicava ORS®in healthy adult subjects under fasted conditions.In this study, 30 healthy adult subjects will receive TTYP01, or Radicava, orRadicava ORS in each period according to the randomization sequence. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RADICAVA
Condition Name
Clinical Trial Locations for RADICAVA
Trials by Country
Clinical Trial Progress for RADICAVA
Clinical Trial Phase
Clinical Trial Sponsors for RADICAVA
Sponsor Name
